Efficacy of OCTA-H and Octa-Gel Against Herpes Simplex Virus Type 1 Infection

Hesham Mohamed Abdal-Salam Yehia^1, and Said Mahmoud Said²

¹Department of Biotechnology, HST Company, Cairo, Egypt

²Department of Biotechnology, HST Company

Cite this paper:
Hesham Mohamed Abdal-Salam Yehia and Said Mahmoud Said. Efficacy of OCTA-H and Octa-Gel Against Herpes Simplex Virus Type 1 Infection. American Journal of Medical Sciences and Medicine. 2023; 11(4):98-101. doi: 10.12691/ajmsm-11-4-1

Abstract

Herpes simplex virus type 1 (HSV-1) is a member of the Herpesviridae family and is a common human pathogen. Herpes simplex virus type 1 (HSV-1) infection is a highly prevalent viral infection that affects a large portion of the population worldwide. The development of effective antiviral agents to combat HSV-1 is of great importance. In this study, we aimed to evaluate the efficacy of two potential antiviral candidates, OCTA-H and Octa-Gel, against HSV-1 infection. The assay was conducted using a BSC-III cabinet level 3 III under Germfree conditions to ensure accurate assessment of antiviral activity. The results demonstrated that both OCTA-H and Octa-Gel exhibited significant antiviral activity against HSV-1, with OCTA-H demonstrating a higher level of efficacy compared to Octa-Gel. These findings highlight the potential of OCTA-H as a promising candidate for further development as an antiviral agent against HSV-1.

Keywords:
OCTA-H Octa-Gel HSV-1 antiviral activity efficacy

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Qiao, H., Guo, M., Shang, J., Zhao, W., Wang, Z., Liu, N., ... & Chen, P. (2020). Herpes simplex virus type 1 infection leads to neurodevelopmental disorder-associated neuropathological changes. PLoS pathogens, 16(10), e1008899.
[2]	Petti, S., & Lodi, G. (2019). The controversial natural history of oral herpes simplex virus type 1 infection. Oral diseases, 25(8), 1850-1865.
[3]	Reinert, L. S., Rashidi, A. S., Tran, D. N., Katzilieris-Petras, G., Hvidt, A. K., Gohr, M., ... & Paludan, S. R. (2021). Brain immune cells undergo cGAS/STING-dependent apoptosis during herpes simplex virus type 1 infection to limit type I IFN production. The Journal of clinical investigation, 131(1).
[4]	Li Puma, D. D., Piacentini, R., Leone, L., Gironi, K., Marcocci, M. E., De Chiara, G., ... & Grassi, C. (2019). Herpes simplex virus type-1 infection impairs adult hippocampal neurogenesis via amyloid-β protein accumulation. Stem cells, 37(11), 1467-1480.
[5]	Urbancikova, I., Hudackova, D., Majtan, J., Rennerova, Z., Banovcin, P., & Jesenak, M. (2020). Efficacy of pleuran (β-glucan from Pleurotus ostreatus) in the management of herpes simplex virus type 1 infection. Evidence-Based Complementary and Alternative Medicine, 2020.
[6]	Duarte, L. F., Farías, M. A., Álvarez, D. M., Bueno, S. M., Riedel, C. A., & González, P. A. (2019). Herpes simplex virus type 1 infection of the central nervous system: insights into proposed interrelationships with neurodegenerative disorders. Frontiers in Cellular Neuroscience, 13, 46.
[7]	Alandijany, T. (2019). Host intrinsic and innate intracellular immunity during herpes simplex virus type 1 (HSV-1) infection. Frontiers in microbiology, 10, 2611.
[8]	Bello-Morales, R., Andreu, S., & López-Guerrero, J. A. (2020). The role of herpes simplex virus type 1 infection in demyelination of the central nervous system. International Journal of Molecular Sciences, 21(14), 5026.
[9]	Forbes, H., Warne, B., Doelken, L., Brenner, N., Waterboer, T., Luben, R., ... & Gkrania-Klotsas, E. (2019). Risk factors for herpes simplex virus type-1 infection and reactivation: Cross-sectional studies among EPIC-Norfolk participants. PLoS One, 14(5), e0215553.
[10]	Tavakoli, A., & Hashemzadeh, M. S. (2020). Inhibition of herpes simplex virus type 1 by copper oxide nanoparticles. Journal of virological methods, 275, 113688.
[11]	Linard, M., Letenneur, L., Garrigue, I., Doize, A., Dartigues, J. F., & Helmer, C. (2020). Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease. Alzheimer's & Dementia, 16(1), 200-208.
[12]	Pouyan, P., Nie, C., Bhatia, S., Wedepohl, S., Achazi, K., Osterrieder, N., & Haag, R. (2021). Inhibition of Herpes Simplex Virus Type 1 Attachment and Infection by Sulfated Polyglycerols with Different Architectures. Biomacromolecules, 22(4), 1545-1554.
[13]	De Chiara, G., Piacentini, R., Fabiani, M., Mastrodonato, A., Marcocci, M. E., Limongi, D., ... & Palamara, A. T. (2019). Recurrent herpes simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice. PLoS pathogens, 15(3), e1007617.
[14]	Magdaleno-Tapial, J., Hernández-Bel, P., Valenzuela-Oñate, C., Ortiz-Salvador, J. M., García-Legaz-Martínez, M., Martínez-Domenech, Á., ... & Pérez-Ferriols, A. (2020). Genital infection with herpes simplex virus type 1 and type 2 in Valencia, Spain: a retrospective observational study. Actas Dermo-Sifiliográficas (English Edition), 111(1), 53-58.
[15]	Luo, Z., Kuang, X. P., Zhou, Q. Q., Yan, C. Y., Li, W., Gong, H. B., ... & He, R. R. (2020). Inhibitory effects of baicalein against herpes simplex virus type 1. Acta Pharmaceutica Sinica B, 10(12), 2323-2338.
[16]	Danastas, K., Miranda-Saksena, M., & Cunningham, A. L. (2020). Herpes simplex virus type 1 interactions with the interferon system. International journal of molecular sciences, 21(14), 5150.
[17]	Karaba, A. H., Figueroa, A., Massaccesi, G., Botto, S., DeFilippis, V. R., & Cox, A. L. (2020). Herpes simplex virus type 1 inflammasome activation in proinflammatory human macrophages is dependent on NLRP3, ASC, and caspase-1. PLoS One, 15(2), e0229570.
[18]	Looker, K. J., Magaret, A. S., May, M. T., Turner, K. M., Vickerman, P., Newman, L. M., & Gottlieb, S. L. (2017). First estimates of the global and regional incidence of neonatal herpes infection. The Lancet Global Health, 5(3), e300-e309.
[19]	Mehmood, A., Kaushik, A. C., & Wei, D. Q. (2019). Prediction and validation of potent peptides against herpes simplex virus type 1 via immunoinformatic and systems biology approach. Chemical Biology & Drug Design, 94(5), 1868-1883.
[20]	Powell-Doherty, R. D., Abbott, A. R., Nelson, L. A., & Bertke, A. S. (2020). Amyloid-β and p-tau anti-threat response to herpes simplex virus 1 infection in primary adult murine hippocampal neurons. Journal of virology, 94(9), 10-1128.
[21]	Yan, C., Luo, Z., Li, W., Li, X., Dallmann, R., Kurihara, H., ... & He, R. R. (2020). Disturbed Yin–Yang balance: Stress increases the susceptibility to primary and recurrent infections of herpes simplex virus type 1. Acta Pharmaceutica Sinica B, 10(3), 383-398.
[22]	Yehia, H. M. A. S., Said, S. M., & Ragb, N. G. E. R. (2022). Silica nanoparticles in targeted human cancer therapy. Medical Journal of Cell Biology, (1), 7-17.
[23]	Yehia, H. M., & Said, S. M. (2021). Effects of the addition of titanium dioxide; sodium silicate and silica nanoparticles on the elimination of bacteria and viruses in a physical field. Am J Biomed Res, 9(2), 24-29.
[24]	Löhr, J. M. (2022). Gastric herpes simplex virus type 1 infection is associated with functional gastrointestinal disorders in the presence and absence of comorbid fibromyalgia. Infection, 50(4), 1043-1043.
[25]	Itzhaki, R. F. (2021). Overwhelming evidence for a major role for herpes simplex virus type 1 (HSV1) in Alzheimer’s disease (AD); underwhelming evidence against. Vaccines, 9(6), 679.
[26]	AlMukdad, S., Harfouche, M., Farooqui, U. S., Aldos, L., & Abu-Raddad, L. J. (2023). Epidemiology of herpes simplex virus type 1 in Canada: systematic review, meta-analyses, and meta-regressions. Frontiers in Public Health, 11, 1118249.
[27]	Yousuf, W., Ibrahim, H., Harfouche, M., Hijleh, F. A., & Abu-Raddad, L. (2020). Herpes simplex virus type 1 in Europe: systematic review, meta-analyses and meta-regressions. BMJ global health, 5(7), e002388.